First Allied Advisory Services’s iShares Biotechnology ETF IBB Stock Holding History

First Allied Advisory Services’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$2.7M	Buy	19,958 +63	+0.3%	+$8.55K	0.09%	228
2020 Q2	$2.72M	Sell	19,895 -1,235	-6%	-$157K	0.1%	214
2020 Q1	$2.28M	Sell	21,130 -1,560	-7%	-$180K	0.1%	216
2019 Q4	$2.73M	Sell	22,690 -865	-4%	-$96.5K	0.09%	248
2019 Q3	$2.34M	Sell	23,555 -2,614	-10%	-$274K	0.08%	265
2019 Q2	$2.85M	Sell	26,169 -1,750	-6%	-$186K	0.1%	233
2019 Q1	$3.12M	Buy	27,919 +4,087	+17%	+$448K	0.11%	218
2018 Q4	$2.28M	Sell	23,832 -327	-1%	-$34.7K	0.09%	244
2018 Q3	$2.94M	Buy	24,159 +2,689	+13%	+$317K	0.1%	226
2018 Q2	$2.36M	Sell	21,470 -9,429	-31%	-$1.01M	0.09%	258
2018 Q1	$3.3M	Sell	30,899 -7,517	-20%	-$833K	0.13%	188
2017 Q4	$4.1M	Buy	38,416 +778	+2%	+$83.2K	0.16%	154
2017 Q3	$4.19M	Sell	37,638 -4,161	-10%	-$445K	0.18%	143
2017 Q2	$4.33M	Buy	41,799 +22,287	+114%	+$2.2M	0.19%	132
2017 Q1	$1.92M	Sell	19,512 -3,549	-15%	-$340K	0.1%	228
2016 Q4	$2.04M	Sell	23,061 -2,682	-10%	-$244K	0.1%	219
2016 Q3	$2.48M	Sell	25,743 -1,059	-4%	-$101K	0.13%	183
2016 Q2	$2.31M	Sell	26,802 -366	-1%	-$32.8K	0.13%	180
2016 Q1	$2.38M	Sell	27,168 -22,245	-45%	-$1.99M	0.13%	174
2015 Q4	$5.55M	Buy	49,413 +9,174	+23%	+$996K	0.29%	85
2015 Q3	$4.07M	Buy	40,239 +3,276	+9%	+$393K	0.22%	115
2015 Q2	$4.54M	Buy	36,963 +2,010	+6%	+$241K	0.2%	133
2015 Q1	$3.99M	Buy	34,953 +12,702	+57%	+$1.4M	0.26%	92
2014 Q4	$2.25M	Sell	22,251 -1,710	-7%	-$166K	0.16%	155
2014 Q3	$2.18M	Sell	23,961 -3,609	-13%	-$317K	0.17%	138
2014 Q2	$2.37M	Sell	27,570 -4,860	-15%	-$383K	0.17%	157
2014 Q1	$2.56M	Buy	32,430 +1,809	+6%	+$151K	0.19%	140
2013 Q4	$2.32M	Buy	30,621 +7,338	+32%	+$521K	0.19%	153
2013 Q3	$1.62M	Buy	23,283 +867	+4%	+$56.8K	0.09%	221
2013 Q2	$1.29M	Buy	+22,416	New	+$1.3M	0.1%	221

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Churchill Management Los Angeles, California $9.21B AUM 19.91% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

First Allied Advisory Services's IBB Position: Q3 2020 in Review

First Allied Advisory Services increased its iShares Biotechnology ETF (IBB) stake by 0.32% in Q3 2020, buying an estimated $8.55K and bringing the position to 19,958 shares worth $2.7M. The position accounts for 0.09% of the portfolio, ranked #228.

First Allied Advisory Services first reported a position in IBB in Q2 2013 and has held it in 30 quarters since. The position peaked at $5.55M in Q4 2015. 783 funds tracked by Wall St. Rank hold IBB as of Q3 2020.

First Allied Advisory Services held 19,958 shares of iShares Biotechnology ETF worth $2.7M as of Q3 2020.
First Allied Advisory Services bought 63 iShares Biotechnology ETF shares in Q3 2020, an estimated $8.55K.
iShares Biotechnology ETF made up 0.09% of First Allied Advisory Services's portfolio in Q3 2020, its #228 holding.
First Allied Advisory Services first reported a position in iShares Biotechnology ETF in Q2 2013 and has held it in 30 quarters since.
First Allied Advisory Services's iShares Biotechnology ETF position peaked at $5.55M in Q4 2015.
783 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2020.

Based on First Allied Advisory Services's 13F filing for Q3 2020, filed 13 Nov 2020.